Frontlight ResearchEarly access
TerminatedPhase 2
A Study of Belcesiran in Patients With AATLD
Key facts
- Who runs it
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Where
- Charleston, Gainesville, and La Jolla, United StatesSee the 3 sitesAlso in 13 other countries, 20 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 16 people enrolled
- Started
- 12 Feb 2021
- Ended
- 29 May 2024
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Belcesiran
- Placebo
- Record updated
- 7 April 2026
- Why it stopped
- Development project was discontinued
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- 18 to 75 years, inclusive, at the time of consent
- Documented diagnosis of PiZZ-type alpha-1 antitrypsin deficiency, confirmed by genotyping. Historical genotyping data may be used, if available
- AATD-associated liver disease documented by liver biopsy at Screening
- Consent to undergo paired liver biopsies
- Lung, renal and liver function within acceptable limits
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
Who cannot take part
- History of one single severe exacerbation of underlying lung disease in the year prior to randomization
- History of clinically significant respiratory infections (including pneumonia and lower respiratory tract infections), as determined by the Investigator, in the 3 months prior to screening
- Use of an RNAi drug at any time
- History of chronic liver disease other than non-alcoholic fatty liver disease from any cause other than PiZZ-type alpha-1 antitrypsin deficiency
- Child-Pugh Score B or C
Where in United States
Also in 13 other countries, 20 sites
- Medical University of South CarolinaCharleston, United States
- University of FloridaGainesville, United States
- University of California San DiegoLa Jolla, United States
About the trial
What the trial wants to find out
This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD).
Read full original descriptionShow less
The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts are differentiated by the duration of the treatment period, the number of doses administered, and the timing of the second liver biopsy.
The 6 groups in the trial
- Belcesiran Cohort 1Treatment being tested
Treatment: Belcesiran
- Placebo Cohort 1Placebo, for comparison
Treatment: Placebo
- Belcesiran Cohort 2Treatment being tested
Treatment: Belcesiran
- Placebo Cohort 2Placebo, for comparison
Treatment: Placebo
- Belcesiran Cohort 3Treatment being tested
Treatment: Belcesiran
- Placebo Cohort 3Placebo, for comparison
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
- Record updated
- 7 April 2026